BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The FDA Modernization Act 2.0 has triggered a new mindset for 
 pharma\, with Roche launching the Institute of Human Biology to create be
 tter models\, and MSD collaborating with Inventia to bioprint 3D in vitro
  models to screen for neurodegenerative therapeutic candidates.\n\nIt has
  never been a more exciting time to bet on 3D tissue models as the future
  of drug development\, as more and more complex in vitro models undergo v
 alidation. However\, the big question of "when can we have the confidence
  in standalone 3D models\, and how to do it at scale?" persists.\n\nMakin
 g its timely return to Boston this May\, the 9th 3D Tissue Models Summit 
 will enable you and your team to uncover best practices across 23+ real-w
 orld applications of complex in vitro models across drug discovery and de
 velopment. Join us to learn from and meet the 'front-line' experts optimi
 zing and leveraging advanced 3D models to confidently empower your own dr
 ug development workflows.\n\nURLs:Tickets: https://go.evvnt.com/2224592-2
 ?pid=185Brochure: https://go.evvnt.com/2224592-3?pid=185\n\nTime: 9:00 AM
  - 2:00 PM\n\nSpeakers: Anastasia Korolj\, PhD\, Chemical and Biomedical 
 Engineer\, Harvard medical school/Massachusetts General Hospital\, Beth H
 offman\, Chief Executive Officer\, Origami Therapeutics\, Inc.\, Bihui Me
 lidosian\, Senior Research Investigator\, Incyte Corporation\, Cindy Chen
 g\, Senior Director - Conjugation and In vitro Evaluation\, Eisai\, Colin
  Choi\, Associate Scientific Director\, Biogen\, David Zhang\, Head of Bi
 oengineering\, ODDITY LABS\, Iosif (Sifis) Pediaditakis\, Associate Direc
 tor of Neuroscience\, Alchemab\, Jason Ekert\, Head of US Discovery Trans
 lational Technology\, UCB S.A.\, Julia Ramirez-Moya\, Scientist\, Alnylam
  Pharmaceuticals\, Katia Karalis\, Executive Director\, Research and Deve
 lopment\, Head of Human Systems for Disease Modeling\, Regeneron Pharmace
 uticals Inc\, Louise Ramos\, Scientist Rakovina Therapeutics\, Inc.\, Man
 ti Guha\, Principal Investigator and CIVM Lead\, Incyte Corporation\, Max
  Friesen\, Postdoctoral Associate\, Whitehead MIT\, Muriel Lize\, Associa
 te Director\, in vitro Respiratory Research\, Boehringer Ingelheim\, Nico
 le Kelly\, Scientist\, Enanta Pharmaceuticals\, Richard Cheng\, Senior Sp
 ecialist\, Engineer\, Merck and Co\, Sai Pavan Grandhi\, Principal Scient
 ist\, Complex In Vitro Models\, GlaxoSmithKline Plc\, Seongmoon Cheong\, 
 Senior Scientist I\, Dicerna\, Serah Kang\, Principal Scientist\, Genente
 ch\, Simone Romoli\, Principal Scientist\, Pfizer\, Tim Spicer\, Director
  of HTS and Discovery Biology\, The Herbert Wertheim UF Scripps Institute
  for Biomedical Innovation and Technology\n
DTEND:20240523T140000
DTSTAMP:20260512T214302Z
DTSTART:20240521T090000
LOCATION:Omni Parker House\, 60\, School Street\, Boston\, Massachusetts\,
  02108\,
SEQUENCE:0
SUMMARY:The FDA Modernization Act 2.0 has triggered a new mindset for phar
 ma\, with Roche launching the Institute of Human Biology to create better
  models\,...
UID:06f47b69-d6c0-4811-8cc8-7421959e1c3e
END:VEVENT
END:VCALENDAR